"Treatment"

H-Drugs in the leading international journal again!

Almost everyone hopes to have a young and healthy heart. However, 62% of people over 40 years old have cardiovascular disease or risk factors to varying degrees, and 80% of them have not yet fully understood how to maintain a healthy heart. Medical research shows that among all internal organs, the heart is most likely to suffer from "obesity", especially in patients with hypertension, which can also lead to gradual thickening of the heart muscle.

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

A dendritic cell vaccine has shown excellent results in the treatment of glioblastoma, significantly extending the survival of patients with a good safety profile, according to new data from a global clinical trial. To date, patients who have benefited for the longest time have survived for more than eight years.

We all know that we need to pay attention to our diet after suffering from a disease, because improper diet will affect the recovery of the disease and the health of the patient.

Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.

Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.

There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.

Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.

Vocal cord cancer often leads to hoarseness, which is a common symptom of many diseases and can be easily overlooked by patients.